Prostate-specific Antigen (PSA) (Serial Monitor)
Use
The Prostate-specific Antigen (PSA) (Serial Monitor) test is used for the long-term serial monitoring of PSA levels in patients undergoing treatment for prostate-related conditions. PSA is a protein produced by both normal and malignant cells of the prostate gland, and its levels in the blood can help in evaluating prostate health. Monitoring PSA levels over time can aid in assessing the effectiveness of treatment, detect potential recurrence of prostate cancer, and guide treatment decisions. It is recommended to use the same assay method consistently for monitoring the patient's course of therapy.
Special Instructions
Not provided.
Limitations
Values obtained with different assay methods or kits cannot be used interchangeably and are not absolute evidence of the presence or absence of malignant disease. Results should be considered in conjunction with other diagnostic procedures and patient history. Assay results should decrease and remain at undetectable levels after radical prostatectomy. The American Urological Association defines biochemical recurrence as an initial PSA value of 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value of 0.2 ng/mL or greater.
Methodology
Immunoassay (ECLIA)
Biomarkers
Prostate Specific Antigen
Protein
LOINC Codes
- 2857-1 - PSA SerPl-mCnc
- 2857-1 - PSA SerPl-mCnc
- 80563-0 - Report
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1.5 mL
Container
Serum separator tube (SST)
Collection Instructions
Collect blood in SST. Centrifuge and separate serum within 1 hour. Freeze at -20°C or colder.
Storage Instructions
Freeze serum and ship on dry ice.
Causes for Rejection
Hemolyzed or lipemic samples.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Not stable |
| Refrigerated | Not stable |
| Frozen | 14 days |
Other tests from different labs that may be relevant